Form 4: Pyxis Oncology Director, John Flavin, Acquires Stock Options

Director John Flavin acquired stock options in Pyxis Oncology, Inc. on March 31, 2025.

Summary

• On March 31, 2025, John L Flavin, a director of Pyxis Oncology, Inc., acquired 36,979 stock options with an exercise price of $0.98.
• These options vest 100% on the first anniversary of the grant date, contingent upon continued service.
• Following the transaction, Flavin directly owns 36,979 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating a stock option grant, which is neither overtly positive nor negative.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule implies continued service of the director.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It's common for directors and officers to receive stock options as part of their compensation.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it signals confidence from a company director.

Key Dates

Keywords

stock options, Form 4, director, Pyxis Oncology, PYXS, beneficial ownership, John Flavin